CC 91633
Alternative Names: BMS-986397; CC-91633Latest Information Update: 19 Nov 2021
At a glance
- Originator Celgene Corporation
- Class Antineoplastics; Small molecules
- Mechanism of Action CRBN protein modulators; Ubiquitin protein ligase complex modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 05 Nov 2021 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in USA (PO) (NCT04951778)
- 05 Nov 2021 Phase-I clinical trials in Myelodysplastic syndromes (Second-line therapy or greater) in USA (PO) (NCT04951778)
- 05 Jul 2021 Celgene plans a phase I trial for Acute myeloid leukaemia (Second-line therapy or greater) and Myelodysplastic syndromes (Second-line therapy or greater) in USA and Spain (NCT04951778)